Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01242488 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

A Phase 2 study of Rheumatoid Arthritis, sponsored by UCB Pharma.

Completed
Registry status
Phase 2
Development phase
221
Enrollment target
20
Study locations

NCT01242488 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by UCB Pharma. The registered enrollment target is 221 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01242488, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
Phase 2
Development phase
221 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • BIOLOGICAL CDP6038
  • BIOLOGICAL Tocilizumab (Actemra or RoActemra)

Study Locations (20)

California

  • 127 - Covina
  • 148 - La Jolla
  • 184 - Long Beach
  • 177 - Los Angeles
  • 104 - Palo Alto
  • 149 - Sacramento
  • 158 - San Diego
  • 129 - Santa Maria
  • 164 - Upland
  • 107 - Wildomar

Arizona

  • 166 - Mesa
  • 154 - Paradise Valley
  • 118 - Scottsdale

Connecticut

  • 141 - Hamden
  • 137 - Norwalk
  • 101 - Trumbull

Arkansas

  • 103 - Hot Springs
  • 125 - Jonesboro

Delaware

  • 111 - Lewes

Florida

  • 176 - Aventura

Trial Details

FieldValue
Enrollment Target 221 participants
Start Date 2010-11
Est. Completion 2012-06
Phase Phase 2

Sponsor

UCB Pharma

100 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01242488

The ClinicalTrials.gov registry entry for NCT01242488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (95% lower). The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which CDP6038 is the first listed.

NCT01242488 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01242488 about?

NCT01242488 is a clinical study titled "Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy". The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy.

What is the current status of trial NCT01242488?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2010-11. Estimated completion is 2012-06.

What conditions does trial NCT01242488 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01242488?

The interventions under investigation include: CDP6038 (BIOLOGICAL), Tocilizumab (Actemra or RoActemra) (BIOLOGICAL).

Who is sponsoring clinical trial NCT01242488?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01242488 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.